Frequently Asked Questions

Many patients have similar questions. We have gathered our frequently asked questions on this page. Please take a look to find your answers here.

FAQ about PRRT

Who may benefit from PRRT?

Adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that test positive for somatostatin receptors.

Who is eligible for PRRT?

Not every patient diagnosed with a neuroendocrine tumor is a candidate for PRRT. Your healthcare provider will determine whether having PRRT may be beneficial for you.

Is PRRT safe?

All therapies, including PRRT, have side effects and risks. You should discuss with your healthcare provider the risks and benefits of PRRT and any other therapies you are considering. Your healthcare provider will help you determine whether PRRT is right for you, given your medical history. Please make sure to tell your provider about any prior therapies you have received, as this can play a role in determining the correct therapy and dosage.

How is PRRT administered?
  • PRRT is administered through an IV infusion.
  • A course of treatment typically includes 4 administrations, given 8 weeks apart.
  • Before and during each PRRT treatment, you will also be given amino acids to protect your kidneys from absorbing radiation, and
    medication to help with potential nausea and vomiting during treatment.
  • Each treatment will take several hours and you should be prepared to spend most of the day at the treatment center. You may want to invite a family member or friend to
    keep you company, unless the  reatment center has any specific restrictions. Approx. 5hours
When is PRRT administered?
  • PRRT may be administered when surgery is not an option or when
    other treatments are not effectively slowing down tumor growth.
  • Your doctor will determine if PRRT (LUTATHERA) is appropriate for you by using a gallium 68 dotatate PET/CT scan to confirm that your tumors have the necessary receptors.
  • Before PRRT can be administered, it is necessary to test that you are eligible for treatment based on blood, kidney, and liver function.
  • Key Facts about PRRT Key Facts about PRRT
Where can I get PRRT?

PRRT is administered in an outpatient clinical setting. Your doctor or a patient advocacy group can help you find a location offering PRRT, if it is recommended for you. Please use the Find a facility button throughout this website to locate institutions offering PRRT.

FAQ about the Gallium-68 Scan

What is a PET/CT scan?

A PET/CT scan is a nuclear imaging technique that combines positron emission tomography (PET) and computed tomography (CT) into one image. It is a diagnostic test that can detect tumors. PET/CT scans are different from MRI scans; there are no issues with metal implants or other medical devices, however, it is important to make sure your healthcare provider is aware of any pre-existing conditions.

What is a Gallium-68 PET/CT scan?

A Gallium-68 PET/CT scan uses a drug, also called a radiopharmaceutical, which contains a small amount of radioactive Gallium-68 combined with a peptide that targets NETs. After a scan is conducted with a PET/CT scanner, the scan will be sent to your healthcare provider for interpretation and discussion with you.

Click here to search for the nearest Gallium-68 PET/CT scan location

Is the Gallium-68 PET/CT scan safe?

Individuals are exposed to low levels of radiation from the Gallium-68 during the test. As with any injection, some individuals may experience bleeding, soreness or swelling at the injection site. Allergic reactions to the radiopharmaceutical may occur, but are extremely rare. Healthcare providers can help patients determine whether a Gallium-68 PET/CT scan is right for them, given their medical history.

What does it mean if my Gallium 68 PET/CT scan is clear?

A clear scan may mean you do not have a NET. However, it may not necessarily rule out the possibility – while the vast majority of neuroendocrine tumors have somatostatin receptors on them (to which the Gallium-68 tracer attaches), in some cases the tumors do not have enough of these receptors to see the Gallium-68 tracer on the scan.

Is your question not here? Contact us

We will have achieved our mission when everyone worldwide is aware of neuroendocrine tumors.  Until then the work of the Carcinoid Cancer Foundation is not done!